Migraine: More Than Just a Headache

Article Type
Changed
Tue, 05/21/2019 - 12:13
Display Headline
Migraine: More Than Just a Headache

Click Here to Read Content.

Topics include:

  • Underdiagnosis and Undertreatment of Migraine
  • A Framework for Understanding Burden of Disease
  • Burden and Cost
  • New Insights in Migraine Pathophysiology
USA-334-80258
Sponsor
This content is sponsored by Amgen Inc. and Novartis Pharmaceuticals Corporatio…
Publications
Topics
Sections
Sponsor
This content is sponsored by Amgen Inc. and Novartis Pharmaceuticals Corporatio…
Sponsor
This content is sponsored by Amgen Inc. and Novartis Pharmaceuticals Corporatio…

Click Here to Read Content.

Topics include:

  • Underdiagnosis and Undertreatment of Migraine
  • A Framework for Understanding Burden of Disease
  • Burden and Cost
  • New Insights in Migraine Pathophysiology
USA-334-80258

Click Here to Read Content.

Topics include:

  • Underdiagnosis and Undertreatment of Migraine
  • A Framework for Understanding Burden of Disease
  • Burden and Cost
  • New Insights in Migraine Pathophysiology
USA-334-80258
Publications
Publications
Topics
Article Type
Display Headline
Migraine: More Than Just a Headache
Display Headline
Migraine: More Than Just a Headache
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Mon, 03/05/2018 - 15:30
Un-Gate On Date
Mon, 03/05/2018 - 15:30
Use ProPublica

COPD in Primary Care: Key Considerations for Optimized Management

Article Type
Changed
Tue, 05/21/2019 - 12:13
Display Headline
COPD in Primary Care: Key Considerations for Optimized Management

Click Here to Read the Supplement

 

This supplement provides an overview of 4 key topics critical to the effective manage­ment of COPD in primary care. The articles in this supplement are:

 

 

Dyspnea and Hyperinflation in COPD: Impact on Physical Activity
by Nathaniel Marchetti, DO; and Alan Kaplan, MD

Anxiety and Depression in COPD: Recognition and Management 
by Abebaw Mengistu Yohannes, PhD; Alan Kaplan, MD; and Nicola A. Hanania, MD, MS

Considerations for Optimal Inhaler Device Selection in COPD
by Rajiv Dhand, MD; Tricia Cavanaugh, MD; and Neil Skolnik, MD

Treatment Options for Stable COPD: Current Recommendations and Unmet Needs
by Barbara Yawn, MD, MSc, FAAFP; and Victor Kim, MD

 

 

 

 

Click Here to Read the Supplement

 

 

Sponsor
This supplement is sponsored by AstraZeneca.
Issue
The Journal of Family Practice - 67(2)
Publications
Topics
Sections
Sponsor
This supplement is sponsored by AstraZeneca.
Sponsor
This supplement is sponsored by AstraZeneca.

Click Here to Read the Supplement

 

This supplement provides an overview of 4 key topics critical to the effective manage­ment of COPD in primary care. The articles in this supplement are:

 

 

Dyspnea and Hyperinflation in COPD: Impact on Physical Activity
by Nathaniel Marchetti, DO; and Alan Kaplan, MD

Anxiety and Depression in COPD: Recognition and Management 
by Abebaw Mengistu Yohannes, PhD; Alan Kaplan, MD; and Nicola A. Hanania, MD, MS

Considerations for Optimal Inhaler Device Selection in COPD
by Rajiv Dhand, MD; Tricia Cavanaugh, MD; and Neil Skolnik, MD

Treatment Options for Stable COPD: Current Recommendations and Unmet Needs
by Barbara Yawn, MD, MSc, FAAFP; and Victor Kim, MD

 

 

 

 

Click Here to Read the Supplement

 

 

Click Here to Read the Supplement

 

This supplement provides an overview of 4 key topics critical to the effective manage­ment of COPD in primary care. The articles in this supplement are:

 

 

Dyspnea and Hyperinflation in COPD: Impact on Physical Activity
by Nathaniel Marchetti, DO; and Alan Kaplan, MD

Anxiety and Depression in COPD: Recognition and Management 
by Abebaw Mengistu Yohannes, PhD; Alan Kaplan, MD; and Nicola A. Hanania, MD, MS

Considerations for Optimal Inhaler Device Selection in COPD
by Rajiv Dhand, MD; Tricia Cavanaugh, MD; and Neil Skolnik, MD

Treatment Options for Stable COPD: Current Recommendations and Unmet Needs
by Barbara Yawn, MD, MSc, FAAFP; and Victor Kim, MD

 

 

 

 

Click Here to Read the Supplement

 

 

Issue
The Journal of Family Practice - 67(2)
Issue
The Journal of Family Practice - 67(2)
Publications
Publications
Topics
Article Type
Display Headline
COPD in Primary Care: Key Considerations for Optimized Management
Display Headline
COPD in Primary Care: Key Considerations for Optimized Management
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica

In the Evolving Mystery of BV, an Innovative Oral Treatment Emerges

Article Type
Changed
Mon, 05/04/2020 - 15:48
Display Headline
In the Evolving Mystery of BV, an Innovative Oral Treatment Emerges

Click Here to Read the Supplement

Topics include:

  • BV terminology and treatment over time
  • Current understanding of BV etiology
  • BV consequences
  • BV treatments
  • Future research needs in BV

Author:
Steven E. Chavoustie, MD, FACOG, CCRP

University of Miami

Miller School of Medicine

Miami, Florida

 

Click Here to Read the Supplement

Sponsor
This supplement is sponsored by Symbiomix Therapeutics, LLC (a Lupin Company).
Publications
Topics
Sections
Sponsor
This supplement is sponsored by Symbiomix Therapeutics, LLC (a Lupin Company).
Sponsor
This supplement is sponsored by Symbiomix Therapeutics, LLC (a Lupin Company).

Click Here to Read the Supplement

Topics include:

  • BV terminology and treatment over time
  • Current understanding of BV etiology
  • BV consequences
  • BV treatments
  • Future research needs in BV

Author:
Steven E. Chavoustie, MD, FACOG, CCRP

University of Miami

Miller School of Medicine

Miami, Florida

 

Click Here to Read the Supplement

Click Here to Read the Supplement

Topics include:

  • BV terminology and treatment over time
  • Current understanding of BV etiology
  • BV consequences
  • BV treatments
  • Future research needs in BV

Author:
Steven E. Chavoustie, MD, FACOG, CCRP

University of Miami

Miller School of Medicine

Miami, Florida

 

Click Here to Read the Supplement

Publications
Publications
Topics
Article Type
Display Headline
In the Evolving Mystery of BV, an Innovative Oral Treatment Emerges
Display Headline
In the Evolving Mystery of BV, an Innovative Oral Treatment Emerges
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.

Best of 2017: Top News Articles

Article Type
Changed
Tue, 05/21/2019 - 12:13
Publications
Sections
Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica

Rheumatology News Best of 2017: Top News Highlights

Article Type
Changed
Tue, 05/21/2019 - 12:13

Best of 2017: Top News Highlights is a supplement to Rheumatology News that presents some of the top stories published in the newspaper in 2017.

The ideas and opinions expressed in Best of 2017: Top News Highlights do not necessarily reflect those of the Publisher. Frontline Medical Communications Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

Publications
Sections

Best of 2017: Top News Highlights is a supplement to Rheumatology News that presents some of the top stories published in the newspaper in 2017.

The ideas and opinions expressed in Best of 2017: Top News Highlights do not necessarily reflect those of the Publisher. Frontline Medical Communications Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

Best of 2017: Top News Highlights is a supplement to Rheumatology News that presents some of the top stories published in the newspaper in 2017.

The ideas and opinions expressed in Best of 2017: Top News Highlights do not necessarily reflect those of the Publisher. Frontline Medical Communications Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

Patient-centered risk assessment for ovarian cancer: Individualizing your approach

Article Type
Changed
Tue, 05/21/2019 - 12:13
Display Headline
Patient-centered risk assessment for ovarian cancer: Individualizing your approach
Article PDF
Author and Disclosure Information

Neal M. Lonky, MD, MPH
Clinical Professor
Department of Obstetrics
and Gynecology
University of California, Irvine
Physician Lead, Strategic EMR
Documentation and Analysis
Department of Obstetrics
and Gynecology
Member, Board of Directors
Southern California Permanente
Medical Group
Kaiser Permanente
OBG Management Contributing Editor

Jeanine M. Genkinger, PhD, MHS
Associate Professor
Department of Epidemiology
Columbia University Mailman School of Public Health
New York, New York

Leslie M. Randall, MD
Associate Professor
Division of Gynecologic Oncology
University of California, Irvine,
School of Medicine

Devansu Tewari, MD
Division Director, Gynecologic Oncology
Department of Obstetrics and Gynecology
Kaiser Permanente Orange County
Women’s Health Services
Associate Clinical Professor
University of California, Irvine,
School of Medicine

Jason D. Wright, MD
Sol Goldman Associate Professor and Chief, Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Columbia University College of Physicians and Surgeons
New York, New York


Dr. Lonky reports that he has received grant or research support from Merck & Co.

Dr. Genkinger reports no financial relationships relevant to this article.

Dr. Wright reports that he has served as a consultant to Clovis Oncology and Tesaro Inc.

Dr. Randall and Dr. Tewari report no financial relationships relevant to this article.

Issue
OBG Management - 30(1)
Publications
Page Number
SS1-SS14
Sections
Author and Disclosure Information

Neal M. Lonky, MD, MPH
Clinical Professor
Department of Obstetrics
and Gynecology
University of California, Irvine
Physician Lead, Strategic EMR
Documentation and Analysis
Department of Obstetrics
and Gynecology
Member, Board of Directors
Southern California Permanente
Medical Group
Kaiser Permanente
OBG Management Contributing Editor

Jeanine M. Genkinger, PhD, MHS
Associate Professor
Department of Epidemiology
Columbia University Mailman School of Public Health
New York, New York

Leslie M. Randall, MD
Associate Professor
Division of Gynecologic Oncology
University of California, Irvine,
School of Medicine

Devansu Tewari, MD
Division Director, Gynecologic Oncology
Department of Obstetrics and Gynecology
Kaiser Permanente Orange County
Women’s Health Services
Associate Clinical Professor
University of California, Irvine,
School of Medicine

Jason D. Wright, MD
Sol Goldman Associate Professor and Chief, Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Columbia University College of Physicians and Surgeons
New York, New York


Dr. Lonky reports that he has received grant or research support from Merck & Co.

Dr. Genkinger reports no financial relationships relevant to this article.

Dr. Wright reports that he has served as a consultant to Clovis Oncology and Tesaro Inc.

Dr. Randall and Dr. Tewari report no financial relationships relevant to this article.

Author and Disclosure Information

Neal M. Lonky, MD, MPH
Clinical Professor
Department of Obstetrics
and Gynecology
University of California, Irvine
Physician Lead, Strategic EMR
Documentation and Analysis
Department of Obstetrics
and Gynecology
Member, Board of Directors
Southern California Permanente
Medical Group
Kaiser Permanente
OBG Management Contributing Editor

Jeanine M. Genkinger, PhD, MHS
Associate Professor
Department of Epidemiology
Columbia University Mailman School of Public Health
New York, New York

Leslie M. Randall, MD
Associate Professor
Division of Gynecologic Oncology
University of California, Irvine,
School of Medicine

Devansu Tewari, MD
Division Director, Gynecologic Oncology
Department of Obstetrics and Gynecology
Kaiser Permanente Orange County
Women’s Health Services
Associate Clinical Professor
University of California, Irvine,
School of Medicine

Jason D. Wright, MD
Sol Goldman Associate Professor and Chief, Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Columbia University College of Physicians and Surgeons
New York, New York


Dr. Lonky reports that he has received grant or research support from Merck & Co.

Dr. Genkinger reports no financial relationships relevant to this article.

Dr. Wright reports that he has served as a consultant to Clovis Oncology and Tesaro Inc.

Dr. Randall and Dr. Tewari report no financial relationships relevant to this article.

Article PDF
Article PDF
Issue
OBG Management - 30(1)
Issue
OBG Management - 30(1)
Page Number
SS1-SS14
Page Number
SS1-SS14
Publications
Publications
Article Type
Display Headline
Patient-centered risk assessment for ovarian cancer: Individualizing your approach
Display Headline
Patient-centered risk assessment for ovarian cancer: Individualizing your approach
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Article PDF Media

2018 Directory of VA and DoD Facilities

Article Type
Changed
Tue, 05/21/2019 - 12:13
Digital Edition
Publications
Sections
Digital Edition
Digital Edition
Publications
Publications
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Wed, 07/25/2018 - 13:45
Un-Gate On Date
Wed, 07/25/2018 - 13:45
Use ProPublica
CFC Schedule Remove Status
Wed, 07/25/2018 - 13:45

Management of Acute Coronary Syndromes in Patients with Diabetes

Article Type
Changed
Tue, 05/21/2019 - 12:13
Display Headline
Management of Acute Coronary Syndromes in Patients with Diabetes

The Cardiovascular Insights for Primary Care Physicians eNewsletter Series summarizes key information and data on common cardiovascular issues facing primary care physicians today. 

Management of Acute Coronary Syndromes in Patients with Diabetes is the fifth eNewsletter in this series.

Click here to read the supplement. 

Sponsor
Funding for this newsletter series was provided by AstraZeneca.
Issue
The Journal of Family Practice - 66(12)
Publications
Sections
Sponsor
Funding for this newsletter series was provided by AstraZeneca.
Sponsor
Funding for this newsletter series was provided by AstraZeneca.

The Cardiovascular Insights for Primary Care Physicians eNewsletter Series summarizes key information and data on common cardiovascular issues facing primary care physicians today. 

Management of Acute Coronary Syndromes in Patients with Diabetes is the fifth eNewsletter in this series.

Click here to read the supplement. 

The Cardiovascular Insights for Primary Care Physicians eNewsletter Series summarizes key information and data on common cardiovascular issues facing primary care physicians today. 

Management of Acute Coronary Syndromes in Patients with Diabetes is the fifth eNewsletter in this series.

Click here to read the supplement. 

Issue
The Journal of Family Practice - 66(12)
Issue
The Journal of Family Practice - 66(12)
Publications
Publications
Article Type
Display Headline
Management of Acute Coronary Syndromes in Patients with Diabetes
Display Headline
Management of Acute Coronary Syndromes in Patients with Diabetes
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica

Optimal Duration of Antiplatelet Therapy Following Acute Coronary Syndrome

Article Type
Changed
Tue, 05/21/2019 - 12:13
Display Headline
Optimal Duration of Antiplatelet Therapy Following Acute Coronary Syndrome

The Cardiovascular Insights for Primary Care Physicians eNewsletter Series summarizes key information and data on common cardiovascular issues facing primary care physicians today. 

Optimal Duration of Antiplatelet Therapy Following Acute Coronary Syndrome is the fourth eNewsletter in this series.

Click here to read the supplement. 

Sponsor
Funding for this newsletter series was provided by AstraZeneca.
Issue
The Journal of Family Practice - 66(12)
Publications
Sections
Sponsor
Funding for this newsletter series was provided by AstraZeneca.
Sponsor
Funding for this newsletter series was provided by AstraZeneca.

The Cardiovascular Insights for Primary Care Physicians eNewsletter Series summarizes key information and data on common cardiovascular issues facing primary care physicians today. 

Optimal Duration of Antiplatelet Therapy Following Acute Coronary Syndrome is the fourth eNewsletter in this series.

Click here to read the supplement. 

The Cardiovascular Insights for Primary Care Physicians eNewsletter Series summarizes key information and data on common cardiovascular issues facing primary care physicians today. 

Optimal Duration of Antiplatelet Therapy Following Acute Coronary Syndrome is the fourth eNewsletter in this series.

Click here to read the supplement. 

Issue
The Journal of Family Practice - 66(12)
Issue
The Journal of Family Practice - 66(12)
Publications
Publications
Article Type
Display Headline
Optimal Duration of Antiplatelet Therapy Following Acute Coronary Syndrome
Display Headline
Optimal Duration of Antiplatelet Therapy Following Acute Coronary Syndrome
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica

CME: Current Treatment Strategies for Advanced Prostate Cancer

Article Type
Changed
Tue, 05/21/2019 - 12:13

Click here to read the supplement.

This activity is supported by an educational grant from Astellas and Medivation, Inc. a Pfizer company, Janssen Biotech, Inc., administered byJanssen Scientific Affairs, LLC. and Sanofi Genzyme.

In this CME supplement, you will learn to:

  • Identify best practices for integrating currently available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
  • Describe new management options for metastatic hormonesensitive prostate cancer (mHSPC)
  • Outline considerations for current and emerging therapies in the management of patients with metastatic castration-resistant prostate cancer (mCSPC)
  • Understand how the molecular and biochemical underpinnings of mCRPC can impact treatment course and selection

 

Click here to read the supplement.

 

After reading, take the posttest evaluation at https://www.surveymonkey.com/r/WMMYNHP

Article PDF
Publications
Topics
Sections
Article PDF
Article PDF

Click here to read the supplement.

This activity is supported by an educational grant from Astellas and Medivation, Inc. a Pfizer company, Janssen Biotech, Inc., administered byJanssen Scientific Affairs, LLC. and Sanofi Genzyme.

In this CME supplement, you will learn to:

  • Identify best practices for integrating currently available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
  • Describe new management options for metastatic hormonesensitive prostate cancer (mHSPC)
  • Outline considerations for current and emerging therapies in the management of patients with metastatic castration-resistant prostate cancer (mCSPC)
  • Understand how the molecular and biochemical underpinnings of mCRPC can impact treatment course and selection

 

Click here to read the supplement.

 

After reading, take the posttest evaluation at https://www.surveymonkey.com/r/WMMYNHP

Click here to read the supplement.

This activity is supported by an educational grant from Astellas and Medivation, Inc. a Pfizer company, Janssen Biotech, Inc., administered byJanssen Scientific Affairs, LLC. and Sanofi Genzyme.

In this CME supplement, you will learn to:

  • Identify best practices for integrating currently available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
  • Describe new management options for metastatic hormonesensitive prostate cancer (mHSPC)
  • Outline considerations for current and emerging therapies in the management of patients with metastatic castration-resistant prostate cancer (mCSPC)
  • Understand how the molecular and biochemical underpinnings of mCRPC can impact treatment course and selection

 

Click here to read the supplement.

 

After reading, take the posttest evaluation at https://www.surveymonkey.com/r/WMMYNHP

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Use ProPublica
Hide sidebar & use full width
render the right sidebar.
Article PDF Media